vs
自然阳光（NATR）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
自然阳光的季度营收约是RESOURCES CONNECTION, INC.的1.1倍（$123.8M vs $117.7M），自然阳光净利率更高（3.3% vs -10.8%，领先14.1%），自然阳光同比增速更快（4.7% vs -19.2%），RESOURCES CONNECTION, INC.自由现金流更多（$15.6M vs $7.6M），过去两年自然阳光的营收复合增速更高（5.6% vs -11.8%）
自然阳光产品公司（简称NSP）主营膳食补充剂与个人护理产品的生产制造，产品涵盖草本补充剂、维生素、矿物质制剂等品类。公司总部设于犹他州利希，生产工厂位于犹他州西班牙福克，是该领域知名的健康产品生产商。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
NATR vs RGP — 直观对比
营收规模更大
NATR
是对方的1.1倍
$117.7M
营收增速更快
NATR
高出23.9%
-19.2%
净利率更高
NATR
高出14.1%
-10.8%
自由现金流更多
RGP
多$8.0M
$7.6M
两年增速更快
NATR
近两年复合增速
-11.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $123.8M | $117.7M |
| 净利润 | $4.1M | $-12.7M |
| 毛利率 | 72.5% | 37.1% |
| 营业利润率 | 4.3% | -10.3% |
| 净利率 | 3.3% | -10.8% |
| 营收同比 | 4.7% | -19.2% |
| 净利润同比 | 1379.4% | 81.6% |
| 每股收益（稀释后） | $0.23 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NATRRGP
| Q4 25 | $123.8M | $117.7M | ||
| Q3 25 | $128.3M | $120.2M | ||
| Q2 25 | $114.8M | $139.3M | ||
| Q1 25 | $113.2M | $129.4M | ||
| Q4 24 | $118.2M | $145.6M | ||
| Q3 24 | $114.6M | $136.9M | ||
| Q2 24 | $110.6M | $148.2M | ||
| Q1 24 | $111.0M | $151.3M |
净利润NATRRGP
| Q4 25 | $4.1M | $-12.7M | ||
| Q3 25 | $5.3M | $-2.4M | ||
| Q2 25 | $5.3M | $-73.3M | ||
| Q1 25 | $4.7M | $-44.1M | ||
| Q4 24 | $-321.0K | $-68.7M | ||
| Q3 24 | $4.3M | $-5.7M | ||
| Q2 24 | $1.3M | $10.5M | ||
| Q1 24 | $2.3M | $2.5M |
毛利率NATRRGP
| Q4 25 | 72.5% | 37.1% | ||
| Q3 25 | 73.3% | 39.5% | ||
| Q2 25 | 71.7% | 40.2% | ||
| Q1 25 | 72.1% | 35.1% | ||
| Q4 24 | 72.0% | 38.5% | ||
| Q3 24 | 71.3% | 36.5% | ||
| Q2 24 | 71.4% | 40.2% | ||
| Q1 24 | 71.2% | 37.0% |
营业利润率NATRRGP
| Q4 25 | 4.3% | -10.3% | ||
| Q3 25 | 7.0% | -1.7% | ||
| Q2 25 | 3.7% | -47.0% | ||
| Q1 25 | 5.4% | -38.4% | ||
| Q4 24 | 3.8% | -52.7% | ||
| Q3 24 | 4.6% | -3.5% | ||
| Q2 24 | 5.1% | 7.6% | ||
| Q1 24 | 4.2% | 2.8% |
净利率NATRRGP
| Q4 25 | 3.3% | -10.8% | ||
| Q3 25 | 4.2% | -2.0% | ||
| Q2 25 | 4.6% | -52.6% | ||
| Q1 25 | 4.2% | -34.0% | ||
| Q4 24 | -0.3% | -47.2% | ||
| Q3 24 | 3.8% | -4.2% | ||
| Q2 24 | 1.2% | 7.1% | ||
| Q1 24 | 2.1% | 1.7% |
每股收益（稀释后）NATRRGP
| Q4 25 | $0.23 | $-0.38 | ||
| Q3 25 | $0.30 | $-0.07 | ||
| Q2 25 | $0.28 | $-2.21 | ||
| Q1 25 | $0.25 | $-1.34 | ||
| Q4 24 | $-0.02 | $-2.08 | ||
| Q3 24 | $0.23 | $-0.17 | ||
| Q2 24 | $0.07 | $0.31 | ||
| Q1 24 | $0.12 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $93.9M | $89.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $161.6M | $194.6M |
| 总资产 | $261.1M | $289.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NATRRGP
| Q4 25 | $93.9M | $89.8M | ||
| Q3 25 | $95.6M | $77.5M | ||
| Q2 25 | $81.3M | $86.1M | ||
| Q1 25 | $86.5M | $72.5M | ||
| Q4 24 | $84.7M | $78.2M | ||
| Q3 24 | $78.7M | $89.6M | ||
| Q2 24 | $68.7M | $108.9M | ||
| Q1 24 | $77.8M | $113.8M |
总债务NATRRGP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $2.1M | — |
股东权益NATRRGP
| Q4 25 | $161.6M | $194.6M | ||
| Q3 25 | $166.7M | $206.4M | ||
| Q2 25 | $163.7M | $207.1M | ||
| Q1 25 | $167.1M | $277.8M | ||
| Q4 24 | $161.0M | $325.7M | ||
| Q3 24 | $162.6M | $407.2M | ||
| Q2 24 | $156.4M | $418.8M | ||
| Q1 24 | $159.7M | $414.9M |
总资产NATRRGP
| Q4 25 | $261.1M | $289.3M | ||
| Q3 25 | $264.8M | $287.2M | ||
| Q2 25 | $254.9M | $304.7M | ||
| Q1 25 | $252.7M | $375.6M | ||
| Q4 24 | $240.9M | $424.9M | ||
| Q3 24 | $245.3M | $512.9M | ||
| Q2 24 | $235.8M | $510.9M | ||
| Q1 24 | $247.3M | $523.2M |
负债/权益比NATRRGP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.9M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $7.6M | $15.6M |
| 自由现金流率自由现金流/营收 | 6.1% | 13.2% |
| 资本支出强度资本支出/营收 | 1.9% | 0.3% |
| 现金转化率经营现金流/净利润 | 2.41× | — |
| 过去12个月自由现金流最近4个季度 | $28.8M | $24.3M |
8季度趋势，按日历期对齐
经营现金流NATRRGP
| Q4 25 | $9.9M | $15.9M | ||
| Q3 25 | $18.5M | $-7.8M | ||
| Q2 25 | $4.3M | $16.8M | ||
| Q1 25 | $2.6M | $659.0K | ||
| Q4 24 | $12.2M | $1.8M | ||
| Q3 24 | $9.6M | $-309.0K | ||
| Q2 24 | $1.3M | $3.2M | ||
| Q1 24 | $2.2M | $20.5M |
自由现金流NATRRGP
| Q4 25 | $7.6M | $15.6M | ||
| Q3 25 | $16.8M | $-8.0M | ||
| Q2 25 | $3.0M | $16.5M | ||
| Q1 25 | $1.5M | $238.0K | ||
| Q4 24 | $10.0M | $61.0K | ||
| Q3 24 | $7.9M | $-575.0K | ||
| Q2 24 | $-2.0M | $3.0M | ||
| Q1 24 | $-1.5M | $20.4M |
自由现金流率NATRRGP
| Q4 25 | 6.1% | 13.2% | ||
| Q3 25 | 13.1% | -6.6% | ||
| Q2 25 | 2.6% | 11.8% | ||
| Q1 25 | 1.3% | 0.2% | ||
| Q4 24 | 8.5% | 0.0% | ||
| Q3 24 | 6.9% | -0.4% | ||
| Q2 24 | -1.9% | 2.1% | ||
| Q1 24 | -1.4% | 13.5% |
资本支出强度NATRRGP
| Q4 25 | 1.9% | 0.3% | ||
| Q3 25 | 1.3% | 0.1% | ||
| Q2 25 | 1.2% | 0.2% | ||
| Q1 25 | 1.0% | 0.3% | ||
| Q4 24 | 1.9% | 1.2% | ||
| Q3 24 | 1.5% | 0.2% | ||
| Q2 24 | 3.0% | 0.1% | ||
| Q1 24 | 3.3% | 0.1% |
现金转化率NATRRGP
| Q4 25 | 2.41× | — | ||
| Q3 25 | 3.46× | — | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.21× | — | ||
| Q2 24 | 0.97× | 0.30× | ||
| Q1 24 | 0.94× | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
